Roma-Rodrigues Catarina, Rivas-García Lorenzo, Baptista Pedro V, Fernandes Alexandra R
UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Campus de Caparica, 2829-516 Caparica, Portugal.
Biomedical Research Centre, Institute of Nutrition and Food Technology, Department of Physiology, Faculty of Pharmacy, University of Granada, Avda. del Conocimiento s/n. 18071 Armilla, Granada, Spain.
Pharmaceutics. 2020 Mar 5;12(3):233. doi: 10.3390/pharmaceutics12030233.
The proposal of gene therapy to tackle cancer development has been instrumental for the development of novel approaches and strategies to fight this disease, but the efficacy of the proposed strategies has still fallen short of delivering the full potential of gene therapy in the clinic. Despite the plethora of gene modulation approaches, e.g., gene silencing, antisense therapy, RNA interference, gene and genome editing, finding a way to efficiently deliver these effectors to the desired cell and tissue has been a challenge. Nanomedicine has put forward several innovative platforms to overcome this obstacle. Most of these platforms rely on the application of nanoscale structures, with particular focus on nanoparticles. Herein, we review the current trends on the use of nanoparticles designed for cancer gene therapy, including inorganic, organic, or biological (e.g., exosomes) variants, in clinical development and their progress towards clinical applications.
提出基因疗法来应对癌症发展,对开发对抗这种疾病的新方法和策略起到了推动作用,但所提出策略的疗效仍未达到在临床上充分发挥基因疗法潜力的程度。尽管有大量的基因调节方法,如基因沉默、反义疗法、RNA干扰、基因和基因组编辑,但找到一种将这些效应物有效递送至所需细胞和组织的方法一直是一项挑战。纳米医学已经提出了几个创新平台来克服这一障碍。这些平台大多依赖于纳米级结构的应用,尤其侧重于纳米颗粒。在此,我们综述了用于癌症基因治疗的纳米颗粒(包括无机、有机或生物(如外泌体)变体)在临床开发中的当前使用趋势及其在临床应用方面的进展。